1. Hammad TA, Neyarapally GA, Iyasu S, Staffa JA, Del Pan G. The future of population-based postmarket drug risk assessment: a regulator’s perspective. Clin Pharmacol Ther. 2013;94(3):349–58.
2. Woodcock J. CDER 2016 Priorities.
http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM477299.pdf
. Accessed 18 Mar 2016.
3. Prescription Drug User Fee Act Patient-Focused Drug Development; Announcement of Disease Areas for Meetings Conducted in Fiscal Years 2013–2015. Fed Regist. 2013;78:21613–4.
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). June 2015. Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment: Guidance for Industry.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM450229.pdf
. Accessed 18 Mar 2016.
5. US Food and Drug Administration. Structured approach to benefit-risk assessment in drug regulatory decision-making. Draft PDUFA V implementation plan—February 2013. Fiscal years 2013–2017.
http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdf
. Accessed 18 Mar 2016.